# Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab

> **NCT01276379** · PHASE2 · COMPLETED · sponsor: **Grupo Espanol Multidisciplinario del Cancer Digestivo** · enrollment: 221 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** FOLFIRI (m)
- **DRUG:** FOLFOX-6 (m)
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT01276379
- **Lead sponsor:** Grupo Espanol Multidisciplinario del Cancer Digestivo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2017-03-15
- **Final completion:** 2017-12-21
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2021-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01276379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01276379, "Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01276379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*